Trius Announces Positive Results from Phase 2 Clinical Trial of Torezolid in Patients with Complicated Skin and Skin Structure Infections
Trius Presents New Data on Torezolid Antibiotic for Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board
Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients with Complicated Skin and Skin Structure Infections
Founded in 2004, the 35-employee biopharmaceutical company is working to develop antibacterial drugs to treat infections caused by resistant bacteria. [Read More]
Trius Awarded $28 Million Contract to Develop Novel Antibiotics
